-
1
-
-
36949032298
-
SRC family nonreceptor tyrosine kinases as molecular targets for cancer therapy
-
Johnson FM, Gallick GE. SRC family nonreceptor tyrosine kinases as molecular targets for cancer therapy. Anticancer Agents Med Chem. 2007;7:651-659.
-
(2007)
Anticancer Agents Med Chem
, vol.7
, pp. 651-659
-
-
Johnson, F.M.1
Gallick, G.E.2
-
2
-
-
0027469402
-
Increase in activity and level of pp60c-Src in progressive stages of human colorectal cancer
-
Talamonti MS, Roh MS, Curley SA, Gallick GE. Increase in activity and level of pp60c-Src in progressive stages of human colorectal cancer. J Clin Invest. 1993;91:53-60.
-
(1993)
J Clin Invest
, vol.91
, pp. 53-60
-
-
Talamonti, M.S.1
Roh, M.S.2
Curley, S.A.3
Gallick, G.E.4
-
3
-
-
0033572412
-
Inhibition of Src kinases by a selective tyrosine kinase inhibitor causes mitotic arrest
-
Moasser MM, Srethapakdi M, Sachar KS, Kraker AJ, Rosen N. Inhibition of Src kinases by a selective tyrosine kinase inhibitor causes mitotic arrest. Cancer Res. 1999;59:6145-6152.
-
(1999)
Cancer Res
, vol.59
, pp. 6145-6152
-
-
Moasser, M.M.1
Srethapakdi, M.2
Sachar, K.S.3
Kraker, A.J.4
Rosen, N.5
-
4
-
-
9744242077
-
Inhibition of SRC tyrosine kinase as treatment for human pancreatic cancer growing orthotopically in nude mice
-
Yezhelyev MV, Koehl G, Guba M, et al. Inhibition of SRC tyrosine kinase as treatment for human pancreatic cancer growing orthotopically in nude mice. Clin Cancer Res. 2004;10:8028-8036.
-
(2004)
Clin Cancer Res
, vol.10
, pp. 8028-8036
-
-
Yezhelyev, M.V.1
Koehl, G.2
Guba, M.3
-
5
-
-
33644647192
-
Inhibition of SRC expression and activity inhibits tumor progression and metastasis of human pancreatic adenocarcinoma cells in an orthotopic nude mouse model
-
Trevino JG, Summy JM, Lesslie DP, et al. Inhibition of SRC expression and activity inhibits tumor progression and metastasis of human pancreatic adenocarcinoma cells in an orthotopic nude mouse model. Am J Pathol. 2006;168:962-972.
-
(2006)
Am J Pathol
, vol.168
, pp. 962-972
-
-
Trevino, J.G.1
Summy, J.M.2
Lesslie, D.P.3
-
6
-
-
26444468152
-
Dasatinib (BMS-354825) tyrosine kinase inhibitor suppresses invasion and induces cell cycle arrest and apoptosis of head and neck squamous cell carcinoma and non-small cell lung cancer cells
-
Johnson FM, Saigal B, Talpaz M, Donato NJ. Dasatinib (BMS-354825) tyrosine kinase inhibitor suppresses invasion and induces cell cycle arrest and apoptosis of head and neck squamous cell carcinoma and non-small cell lung cancer cells. Clin Cancer Res. 2005;11(19 pt 1):6924-6932.
-
(2005)
Clin Cancer Res
, vol.11
, Issue.19 PART 1
, pp. 6924-6932
-
-
Johnson, F.M.1
Saigal, B.2
Talpaz, M.3
Donato, N.J.4
-
7
-
-
57749172257
-
Src family kinases as mediators of endothelial permeability: Effects on inflammation and metastasis
-
Kim MP, Park SI, Kopetz S, Gallick GE. Src family kinases as mediators of endothelial permeability: effects on inflammation and metastasis. Cell Tissue Res. 2009;335:249-259.
-
(2009)
Cell Tissue Res
, vol.335
, pp. 249-259
-
-
Kim, M.P.1
Park, S.I.2
Kopetz, S.3
Gallick, G.E.4
-
8
-
-
44849134528
-
Targeting SRC family kinases inhibits growth and lymph node metastases of prostate cancer in an orthotopic nude mouse model
-
Park SI, Zhang J, Phillips KA, et al. Targeting SRC family kinases inhibits growth and lymph node metastases of prostate cancer in an orthotopic nude mouse model. Cancer Res. 2008;68:3323-3333.
-
(2008)
Cancer Res
, vol.68
, pp. 3323-3333
-
-
Park, S.I.1
Zhang, J.2
Phillips, K.A.3
-
9
-
-
34447316429
-
Inhibition of c-Src expression and activation in malignant pleural mesothelioma tissues leads to apoptosis, cell cycle arrest, and decreased migration and invasion
-
Tsao AS, He D, Saigal B, et al. Inhibition of c-Src expression and activation in malignant pleural mesothelioma tissues leads to apoptosis, cell cycle arrest, and decreased migration and invasion. Mol Cancer Ther. 2007;6:1962-1972.
-
(2007)
Mol Cancer Ther
, vol.6
, pp. 1962-1972
-
-
Tsao, A.S.1
He, D.2
Saigal, B.3
-
10
-
-
33846241683
-
Identification of potential biomarkers for measuring inhibition of Src kinase activity in colon cancer cells following treatment with dasatinib
-
Serrels A, Macpherson IR, Evans TR, et al. Identification of potential biomarkers for measuring inhibition of Src kinase activity in colon cancer cells following treatment with dasatinib. Mol Cancer Ther. 2006;5:3014-3022.
-
(2006)
Mol Cancer Ther
, vol.5
, pp. 3014-3022
-
-
Serrels, A.1
Macpherson, I.R.2
Evans, T.R.3
-
11
-
-
56449100212
-
Inhibition of SRC family kinases with dasatinib blocks migration and invasion of human melanoma cells
-
Buettner R, Mesa T, Vultur A, Lee F, Jove R. Inhibition of SRC family kinases with dasatinib blocks migration and invasion of human melanoma cells. Mol Cancer Res. 2008;6:1766-1774.
-
(2008)
Mol Cancer Res
, vol.6
, pp. 1766-1774
-
-
Buettner, R.1
Mesa, T.2
Vultur, A.3
Lee, F.4
Jove, R.5
-
12
-
-
37249048453
-
Preclinical pharmacokinetics and in vitro metabolism of dasatinib (BMS-354825): A potent oral multi-targeted kinase inhibitor against SRC and BCR-ABL
-
Kamath AV, Wang J, Lee FY, Marathe PH. Preclinical pharmacokinetics and in vitro metabolism of dasatinib (BMS-354825): a potent oral multi-targeted kinase inhibitor against SRC and BCR-ABL. Cancer Chemother Pharmacol. 2008;61:365-376.
-
(2008)
Cancer Chemother Pharmacol
, vol.61
, pp. 365-376
-
-
Kamath, A.V.1
Wang, J.2
Lee, F.Y.3
Marathe, P.H.4
-
13
-
-
49249121723
-
Intermittent target inhibition with dasatinib 100 mg once daily preserves efficacy and improves tolerability in imatinib-resistant and - intolerant chronic-phase chronic myeloid leukemia
-
Shah NP, Kantarjian HM, Kim DW, et al. Intermittent target inhibition with dasatinib 100 mg once daily preserves efficacy and improves tolerability in imatinib-resistant and - intolerant chronic-phase chronic myeloid leukemia. J Clin Oncol. 2008;26:3204-32122.
-
(2008)
J Clin Oncol
, vol.26
, pp. 3204-32122
-
-
Shah, N.P.1
Kantarjian, H.M.2
Kim, D.W.3
-
14
-
-
0032757213
-
Measurement of clinical and subclinical tumour response using [18F]-fluorodeoxyglucose and positron emission tomography: Review and 1999 EORTC recommendations. European Organization for Research and Treatment of Cancer (EORTC) PET Study Group
-
Young H, Baum R, Cremerius U, et al. Measurement of clinical and subclinical tumour response using [18F]-fluorodeoxyglucose and positron emission tomography: review and 1999 EORTC recommendations. European Organization for Research and Treatment of Cancer (EORTC) PET Study Group. Eur J Cancer. 1999;35:1773-1782.
-
(1999)
Eur J Cancer
, vol.35
, pp. 1773-1782
-
-
Young, H.1
Baum, R.2
Cremerius, U.3
-
15
-
-
33646654192
-
Pharmacokinetic-pharmacodynamic modeling in the data analysis and interpretation of drug-induced QT/QTc prolongation [serial online]
-
Piotrovsky V. Pharmacokinetic-pharmacodynamic modeling in the data analysis and interpretation of drug-induced QT/QTc prolongation [serial online]. AAPS J. 2005;7:E609-E624.
-
(2005)
AAPS J
, vol.7
-
-
Piotrovsky, V.1
-
16
-
-
34548523623
-
Pleural effusion in patients with chronic myelogenous leukemia treated with dasatinib after imatinib failure
-
Quintas-Cardama A, Kantarjian H, O'Brien S, et al. Pleural effusion in patients with chronic myelogenous leukemia treated with dasatinib after imatinib failure. J Clin Oncol. 2007;25:3908-3914.
-
(2007)
J Clin Oncol
, vol.25
, pp. 3908-3914
-
-
Quintas-Cardama, A.1
Kantarjian, H.2
O'Brien, S.3
-
17
-
-
33947356135
-
Dasatinib induces complete hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in blast crisis
-
Cortes J, Rousselot P, Kim DW, et al. Dasatinib induces complete hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in blast crisis. Blood. 2007;109:3207-3213.
-
(2007)
Blood
, vol.109
, pp. 3207-3213
-
-
Cortes, J.1
Rousselot, P.2
Kim, D.W.3
-
18
-
-
33745102555
-
Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias
-
Talpaz M, Shah NP, Kantarjian H, et al. Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias. N Engl J Med. 2006;354:2531-2541.
-
(2006)
N Engl J Med
, vol.354
, pp. 2531-2541
-
-
Talpaz, M.1
Shah, N.P.2
Kantarjian, H.3
-
19
-
-
33745914717
-
Phase I dose-escalation study of the SRC and multi-kinase inhibitor BMS-354825 in patients (pts) with GIST and other solid tumors [abstract]
-
Abstract 3034
-
Evans TR, Morgan JA, van den Abbeele AD, et al. Phase I dose-escalation study of the SRC and multi-kinase inhibitor BMS-354825 in patients (pts) with GIST and other solid tumors [abstract]. J Clin Oncol. 2005;23(16S). Abstract 3034.
-
(2005)
J Clin Oncol
, vol.23
, Issue.16 S
-
-
Evans, T.R.1
Morgan, J.A.2
van den Abbeele, A.D.3
-
20
-
-
43449091001
-
Pleural effusions in patients with chronic myeloid leukaemia treated with dasatinib may have an immune-mediated pathogenesis
-
de Lavallade H, Punnialingam S, Milojkovic D, et al. Pleural effusions in patients with chronic myeloid leukaemia treated with dasatinib may have an immune-mediated pathogenesis. Br J Haematol. 2008;141:745-747.
-
(2008)
Br J Haematol
, vol.141
, pp. 745-747
-
-
de Lavallade, H.1
Punnialingam, S.2
Milojkovic, D.3
-
21
-
-
35349001079
-
Lung abnormalities after dasatinib treatment for chronic myeloid leukemia: A case series
-
Bergeron A, Rea D, Levy V, et al. Lung abnormalities after dasatinib treatment for chronic myeloid leukemia: a case series. Am J Respir Crit Care Med. 2007;176:814-818.
-
(2007)
Am J Respir Crit Care Med
, vol.176
, pp. 814-818
-
-
Bergeron, A.1
Rea, D.2
Levy, V.3
-
23
-
-
56149095226
-
A phase I study of dasatinib, a Src multi-kinase inhibitor, in patients with GIST and other solid tumors [abstract]
-
Abstract 383
-
Morgan JA, Demetri G, Wang D, et al. A phase I study of dasatinib, a Src multi-kinase inhibitor, in patients with GIST and other solid tumors [abstract]. Eur J Cancer. 2006;12(suppl 4):118. Abstract 383.
-
(2006)
Eur J Cancer
, vol.12
, Issue.SUPPL. 4
, pp. 118
-
-
Morgan, J.A.1
Demetri, G.2
Wang, D.3
-
24
-
-
77949416487
-
-
Bristol-Myers Squibb Company, Princeton, NJ: Bristol-Myers Squibb Company;
-
Bristol-Myers Squibb Company. SPRYCEL prescribing information. Princeton, NJ: Bristol-Myers Squibb Company; 2008.
-
(2008)
SPRYCEL prescribing information
-
-
-
25
-
-
54349127397
-
Effect of the multitargeted tyrosine kinase inhibitors imatinib, dasatinib, sunitinib, and sorafenib on mitochondrial function in isolated rat heart mitochondria and H9c2 cells
-
Will Y, Dykens JA, Nadanaciva S, et al. Effect of the multitargeted tyrosine kinase inhibitors imatinib, dasatinib, sunitinib, and sorafenib on mitochondrial function in isolated rat heart mitochondria and H9c2 cells. Toxicol Sci. 2008;106: 153-161.
-
(2008)
Toxicol Sci
, vol.106
, pp. 153-161
-
-
Will, Y.1
Dykens, J.A.2
Nadanaciva, S.3
-
26
-
-
0346399929
-
QT and RR intervals in conscious and anesthetized guinea pigs with highly varying RR intervals and given QTc-lengthening test articles
-
Hamlin RL, Kijtawornrat A, Keene BW, Hamlin DM. QT and RR intervals in conscious and anesthetized guinea pigs with highly varying RR intervals and given QTc-lengthening test articles. Toxicol Sci. 2003;76:437-442.
-
(2003)
Toxicol Sci
, vol.76
, pp. 437-442
-
-
Hamlin, R.L.1
Kijtawornrat, A.2
Keene, B.W.3
Hamlin, D.M.4
|